Arsenic is a proven human carcinogen and is associated with a myriad of other adverse health effects. This metalloid is methylated in human liver to monomethylarsonic acid (MMA V ), monomethylarsonous acid (MMA III ), dimethylarsinic acid (DMA V ), and dimethylarsinous acid (DMA III ) and eliminated predominantly in urine. Hepatic basolateral transport of arsenic species is ultimately critical for urinary elimination; however, these pathways are not fully elucidated in humans. A potentially important human hepatic basolateral transporter is the ATP-binding cassette (ABC) transporter multidrug resistance protein 4 (MRP4/ABCC4) that in vitro is a high-affinity transporter of DMA V and the diglutathione conjugate of
The arsenic contamination of groundwater in Bangladesh has been referred to as 'the largest mass poisoning of a population in history' (Smith et al., 2000) . Arsenic is found at levels that exceed the WHO limit of 10 ppb in many other parts of the world and is a Group I (proven) human carcinogen (IARC, 2012; Naujokas et al., 2013) . Exposure to arsenic is also associated with a broad range of other adverse health effects including peripheral vascular disease, neurological disorders, and diabetes mellitus (Naujokas et al., 2013) . Despite the known deleterious health effects caused by arsenic and the prevalence of human exposure, key steps of arsenic toxicokinetics and elimination are not fully understood.
The vast majority of arsenic in contaminated drinking water is inorganic and thus a combination of arsenate (As V ) and arsenite (As III ). Cellular uptake of As V can be mediated by phosphate transporters such as the Na þ /phosphate cotransporter type IIb (SLC34A2) (Villa-Bellosta and Sorribas, 2010), while As III uptake pathways include aquaglyceroporins (AQPs) and glucose transporters (GLUTs) (Mukhopadhyay et al., 2014) . Evidence from AQP9 knock-out mice suggests that AQP9 can function in both the cellular uptake and efflux of neutral arsenic species (Mukhopadhyay et al., 2014) . Once inside human cells, the methylation of arsenic is catalyzed by the enzyme arsenic (þ3 oxidation state) methyltransferase, resulting in 4 major products: monomethylarsonic acid (MMA V (Cullen, 2014; Drobna et al., 2010) . Arsenic is methylated predominantly in the liver; however, the majority of arsenic is excreted in human urine. The transport pathways responsible for the basolateral efflux of arsenic from the human hepatocyte into blood for renal elimination have not been characterized in a physiologically relevant human model.
The multidrug resistance proteins MRP1, MRP2, and MRP4 (ABCC1, ABCC2, and ABCC4, respectively) are ATP-binding cassette transporter proteins with established roles as arsenic efflux transporters (Banerjee et al., 2014; Leslie, 2012) . In vivo rat studies have shown that Mrp2 is responsible for the biliary excretion of arsenic as As(GS) 3 and MMA(GS) 2 (Kala et al., 2000) . MRP3, MRP4, MRP5, and MRP6 are localized to the basolateral surface of hepatocytes and can transport substrates from the liver to blood. Recent studies have shown that DMA V and MMA(GS) 2 are high-affinity substrates for MRP4, while MRP3 and MRP5 do not protect cells from inorganic or methylated arsenic species (Banerjee et al., 2014) . The ability of MRP6 to transport or protect cells from arsenic has not been investigated. Primary human hepatocytes cultured in a sandwich configuration (between 2 layers of collagen) have correct polarization and develop extensive functional canalicular networks. Furthermore, sandwich cultured hepatocytes (SCH) retain their metabolic capacity and express transport proteins at levels comparable to hepatocytes in vivo (Ghibellini et al., 2007; Liu et al., 1999b) . The in vivo hepatobiliary clearance of xenobiotics in humans and rats and the corresponding in vitro biliary clearance in SCH are highly correlated, making this physiological model ideal for studying human hepatobiliary transport of arsenic (Ghibellini et al., 2007; Liu et al., 1999a) . Thus, in this study, arsenic hepatobiliary transport was characterized using sandwich cultured primary human hepatocytes (SCHH). The basolateral efflux of arsenic was detected in all 14 SCHH preparations characterized, and 5 of these preparations also effluxed arsenic across the canalicular membrane. Speciation of basolateral efflux media revealed that SCHH methylate arsenic and the inorganic, monomethylated, and dimethylated forms are transported. The results presented suggest basolateral efflux of arsenic is mediated at least in part by one or more MRPs, and one likely candidate is MRP4. Furthermore, results suggest that basolateral efflux of arsenic prevails over its biliary excretion.
MATERIALS AND METHODS

Materials.
73
As V (5.45 mCi/mL) was purchased from Los Alamos
Meson Production Facility (Los Alamos, New Mexico).
[ 3 H(G)]-Taurocholic acid (5.0 Ci/mmol) and [6, The human embryonic kidney (HEK 293) cell line was maintained in DMEM supplemented with 4 mM L-glutamine and 7.5% FBS in a humidified incubator with 95% air/ 5% CO 2 .
Human hepatocyte isolation and culture. Human liver tissue was obtained from adult (>18 years) patients undergoing hepatic resection at the University of Alberta Hospital (Edmonton, Alberta) by qualified medical staff with the approval of the University of Alberta human ethics review board. Patients were free of infectious disease (Hepatitis B/C and HIV) and significant liver disease. Hepatocytes from livers were isolated using a modified 2-step collagenase perfusion method [ (Hamilton et al., 2001) for livers [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] and [(Mercer et al., 2001 ) for livers [21] [22] [23] [24] [25] [26] and cultured according to previously described methods (Ghibellini et al., 2007) , with alterations. Viabilities of the isolated primary human hepatocytes were estimated by trypan blue exclusion (Table 1) . Cells were seeded on 6-or 12-well Biocoat culture plates at 1.5 Â 10 6 or 6.25 Â 10 5 cells/well, respectively, in seeding media (phenol red-free DMEM supplemented with 5% FBS, 0.1 mM modified essential medium nonessential amino acids, 2 mM L-glutamine, 100 U/ml penicillin, 100 lg/ml streptomycin, 4 lg/ml human recombinant insulin, 1 lM dexamethasone) and maintained at 37 C in a humidified incubator with 95% air/5% CO 2 . After cell attachment to plates (2-4 h postseeding) media was replaced with media 2: phenol red-free DMEM supplemented as above except with 0.1 mM dexamethasone, ITS þ (6.25 lg/ml insulin, 6.25 lg/ml transferrin, 6.25 ng/ml selenium) and no FBS. This media composition was used for the rest of the time in culture. Cells were overlaid 12-16 h postseeding with 0.25 mg/ml Matrigel in 1.5 ml of ice-cold medium.
Cultures were maintained with daily media changes for 6 days prior to use in experiments.
SCHH accumulation and efflux studies. SCHH were cultured for 6 days to allow for maximum development of canalicular networks and limit variability due to donor health, life-style and xenobiotic exposure (Drobna et al., 2010; Ghibellini et al., 2007) .
On day 5, SCHH were incubated with 73 As III (0.1-1 lM, 100 nCi/well) in media 2 for 24 h to allow accumulation and metabolism of arsenic.
As III was prepared from 73 As V using metabisulfite-thiosulfate reducing agent as previously described (Reay and Asher, 1977) . To measure arsenic accumulation
As III (1 lM, 100 nCi/well) containing media was removed and cells were washed thrice with 4 C standard HBSS. Cells were then lysed with 0.5% Triton X-100 and 500 ml was analyzed by liquid scintillation counting. Arsenic efflux experiments were performed as previously described (Kostrubsky et al., 2003) . Cells were washed twice with 4 C standard HBSS and efflux of arsenic across the hepatocyte basolateral surface was initiated by the addition of 1 ml of 37 C fresh standard HBSS. In parallel, efflux from both basolateral and canalicular surfaces was measured after the addition of 1 ml 37 C Ca (Liu et al., 1999c) . Plates were incubated at 37 C and HBSS (100 ll) was sampled at the indicated time points. Samples were placed in scintillation vials and quantified by liquid scintillation counting. Accumulation and efflux activity was normalized for total hepatocyte protein determined using a BCA assay. H-taurocholate (1 mM, 100 nCi/ well) was done for 15 min instead of 24 h. For all experimental conditions, cytotoxicity was monitored by measuring the release of lactate dehydrogenase (LDH) using the Cytotoxicity Detection Kit (Roche, Mississuaga, ON), as described previously (Lee et al., 2008) . The degree of LDH release was calculated as a percentage of the maximum cellular LDH release, which was measured by adding 2% Triton X-100 to SCHH based on equation 1 below.
When LDH was detected, >5% cytotoxicity was considered unacceptable and transport data was omitted.
The biliary excretion index (BEI) for arsenic and taurocholate efflux was calculated based on equation 2 below [adapted for efflux from (Liu et al., 1999b) ].
Fluorescence microscopy. SCHH were seeded onto 12-well Biocoat plates and cultured as described earlier. Cells were treated with As III under conditions identical to transport assays. On day 6 of culture, cells were washed thrice with 1 ml HBSS (37 C), incubated with 5 (and 6)-carboxy 2 0 ,7 0 dichlorofluorescein (CDF) diacetate (2 mM) for 10 min at 37 C, and washed again thrice with 1 ml HBSS (37 C) followed by the addition of 1 ml HBSS (Liu et al., 1999b) . Cells were then viewed under a fluorescence microscope (Olympus, IX81, Olympus Canada, Richmond Hill, Ontario).
Cell lysate preparation and immunoblotting. As described for transport assays SCHH were incubated with As III (0.1-1 lM), oltipraz (50 mM) or BSO (500 mM). Cells were washed twice with 1 ml PBS, then scraped into 1 ml PBS, spun at 16 000g for 5 min and stored at À80 C. Pellets were thawed on ice and then lysed with RIPA buffer (0.1% SDS, 1% sodium deoxycholate, 1% Triton X-100, 10 mM Tris pH 8.0, 140 mM NaCl) with Complete protease inhibitors for 30 min at 4 C. Nuclei and cell debris were pelleted by centrifugation for 10 min, at 16 000g at 4 C. Proteins (30 lg) were resolved by SDS-PAGE and transferred to a polyvinylidene fluoride (PVDF) membrane. PVDF membranes were blocked at 37 C with 4% nonfat milk in Tris-buffered saline with 0.3% Tween-20, pH 7.4, incubated with either the MRP1-specific monoclonal antibody MRPr1 (1:10,000), the MRP2-specific monoclonal antibody M 2 I-4 (1:2000), the MRP4-specific monoclonal antibody M 4 I-10 (1:500), the MRP6-specific monoclonal antibody M 6 II-7 (1:500), or the AQP9-specific polyclonal antibody [C-18] (1:500) as previously described (Hipfner et al., 1994) . Blots were then stripped and incubated with the Na [H-300] (1:10 000) as a loading control. Densitometry analysis was done using Image J software.
Preparation of membrane vesicles and E217bG transport assays. HEK293 cells were transfected with pcDNA 3.1 (þ) MRP4 using the calcium phosphate method as previously described (Carew and Leslie, 2010) . The full length human MRP4 cDNA was a gift from Dr Dietrich Keppler (German Cancer Research Center, Heidelberg, Germany) (Rius et al., 2003) and was subcloned into pcDNA3.1 (þ) neomycin to generate pcDNA3.1 (þ) MRP4 as previously described (Banerjee et al., 2014) . Plasma membrane enriched membrane vesicles were prepared from MRP4 and empty pcDNA 3.1 (þ) transfected HEK293 cells and E 2 17bG transport inhibition was completed as previously described (Carew et al., 2011) . Briefly, 10 mg of MRP4-enriched membrane vesicles were incubated with [ 3 H]-E 2 17bG (1 mM, 80 nCi/pt), AMP or ATP (4 mM), MgCl 2 (10 mM), creatine phosphate (10 mM), creatine kinase (100 mg/ml), Tris (50 mM, pH 7.4), and sucrose (250 mM) at 37 C for 3 min in the absence or presence of phloretin (50-500 mM). Transport was stopped by diluting with 800 ml ice cold Tris (50 mM, pH 7.4) sucrose (250 mM) buffer, filtering over glass fiber filters, washing twice with 3.5 ml Tris sucrose buffer, and radioactivity was quantified by liquid scintillation counting using a Microbeta 2 counter (PerkinElmer Life and Analytical Sciences). IC 50 values were determined using Graphpad Prism 6.05 Software (nonlinear regression log(inhibitor) vs normalized response analysis).
High-performance liquid chromatography-inductively coupled plasma mass spectrometry analysis of arsenic species in SCHH culture media. SCHH were treated with nonradioactive As III (0.5 or 1 mM) for 24 h in media 2. Media was then collected and immediately stored at À80 C. Hepatocytes were then washed twice with ice cold arsenic-free media and then arsenic-free 37 C media 2 was added and cells incubated for 1 h at 37 C. Media was again collected and stored immediately at À80 C.
An Agilent 1100 series high-performance liquid chromatography (HPLC) system consisting of a pump, degasser, autosampler, column temperature control, and reversed-phase C 18 column (ODS-3, 150 mm Â 4.6 mm, 3-lm particle size; Phenomenex, Torrance, California) was used for the separation of arsenicals. The mobile phase consisted of 5 mM tetrabutylammonium, 5% methanol, and 3 mM malonic acid (pH 5.85). The column was equilibrated with the mobile phase for at least 0.5 h before sample injection. Separation of samples was performed at a flow rate of 1.2 ml/min; 50 ml sample was injected; the column temperature was maintained at 50 C. The effluent from the HPLC was introduced directly into the nebulizer of a 7500ce inductively coupled plasma mass spectrometer (ICP-MS) instrument (Agilent Technologies, Japan) using PEEK tubing. The collision cell of the ICP-MS instrument was operated in helium mode. Helium (3.5 ml/min) was used in the octopole reaction cell to reduce isobaric and polyatomic interferences.
The ICP operated at a radio-frequency power of 1550 W, and the flow rate of carrier gas was 0.9-1.0 l/min. Arsenic was monitored at m/z 75. Chromatograms from HPLC separation were recorded by ICP-MS ChemStation (Agilent Technologies, Santa Clara, California). Certified reference material 18 'Human Urine' was used for quality control. There was good agreement between the certified and analyzed values.
RESULTS
Arsenic Is Transported Across Only the Basolateral Membrane in Certain SCHH Preparations
Large differences exist among animal species in the toxicokinetic pathways and carcinogenic effects of arsenic making it essential to study arsenic transport using relevant human model systems (Tokar et al., 2010) . Thus, SCHH were used to characterize arsenic hepatobiliary efflux pathways. In the presence of calcium, the tight junctions remain fully formed and the canalicular networks intact, allowing for measurement of efflux across the basolateral membrane of the hepatocyte. Removal of calcium from the buffer disrupts the tight junctions and allows measurement of efflux across both the apical and basolateral membranes (Liu et al., 1999c) . A difference in efflux between the plus and minus calcium conditions indicates that there is apical transport of a substrate. The bile acid, taurocholate, undergoes extensive biliary excretion and was used as a positive control for each hepatocyte preparation (to confirm canalicular networks were formed and functional). As expected, there was a significant increase in taurocholate efflux in the absence of calcium when compared with transport in the presence of calcium ( Fig. 1A ; Table 1 ). The BEI for taurocholate ranged from 31 to 70% at 10 min (mean 50 6 9%) (Table 1) , and were similar to previously published values (Ghibellini et al., 2007; Kostrubsky et al., 2003; Marion et al., 2007; Sharma et al., 2013) .
To investigate the hepatobiliary transport of arsenic, SCHH were treated with As III (0.5 or 1 mM, as indicated) for 24 h and then efflux measured as described earlier for taurocholate. The 24 h time point was selected because accumulation of arsenic had reached a plateau by this time ( Supplementary Fig. S1A ). Accumulation in SCHH preparations 2, 4, 5, and 26 at 24 h ranged from 274 to 560 pmol mg (Table 1) . The BEI for SCHH with moderate biliary excretion (preparations 2 and 22) ranged from 17 to 21%, and the more extensive biliary excretion (preparations 19, 21, and 23) ranged from 25 to 39% (Table 1) . It was possible to calculate a BEI for 3 of the SCHH preparations that were classified as 'only basolateral efflux ' (preparations 5, 24, and 26) (Figs. 1E, N, and O) , but the BEI values were low and not detectable at the 3-min time point (Table 1) .
MRP2 Is Functional in SCHH Preparations Lacking Arsenic Biliary Excretion
In vivo studies using Mrp2-deficient Wistar rats have shown that Mrp2 is responsible for all arsenic biliary excretion (Kala et al., 2000) . To determine if the lack of arsenic biliary excretion observed with 9 of the SCHH preparations was due to a lack of functional MRP2, 2 representative SCHH preparations that lacked arsenic biliary excretion, 13 and 24, were tested for their ability to efflux the MRP2 substrate CDF into canalicular networks (Zamek-Gliszczynski et al., 2003) . The fluorescent images clearly show accumulation of CDF in the canalicular networks, suggesting that MRP2 is expressed and functional ( Fig. 2A 
CDF Is Accumulated in Canalicular Networks of SCHH Treated With Arsenic
All SCHH preparations had acceptable canalicular formation and function as assessed by measuring the taurocholate BEI (Table 1) . However, the influence of arsenic on the canalicular network integrity was unknown. To explore the possibility that arsenic was disrupting canalicular networks and preventing arsenic biliary accumulation (in cases where arsenic biliary excretion was not detected), the accumulation and retention of CDF within the canalicular networks of SCHH preparation 13 was imaged after treatment with arsenic (1 mM) and arsenic (1 mM) plus BSO (500 mM) using conditions identical to transport assays (Figs. 2E and F) . The pattern of CDF accumulation in canalicular networks was similar between untreated ( Fig. 2A) , As III treated (Fig. 2E) and As III plus BSO (Fig. 2F ) SCHH preparation 13. These data suggest that the integrity of the canalicular networks was not disrupted by arsenic under the conditions used for transport assays.
Arsenic Concentration Doesn't Change the Polarized Transport of Arsenic
To determine if arsenic efflux remained predominantly basolateral over a concentration range, efflux was measured after treating cells with 0.1 to 1 mM of As III . Decreasing concentrations of As III in SCHH preparations 4, 13, or 16 that lacked biliary excretion at 1 mM of As III resulted in a dose-dependent reduction of basolateral efflux (Figs. 3A-C) ; however, no biliary excretion was detected. SCHH preparation 19 had BEI values of 25, 29, and 38% at 1, 0.5, and 0.1 mM arsenic, respectively (Fig. 3D) , suggesting an increased biliary excretion with decreasing arsenic concentration.
Arsenic Transport Is Temperature Sensitive
Transport proteins do not function at 4 C and thus temperature sensitivity of substrate translocation across cell membranes indicates that a transport process is involved. To evaluate the effect of temperature on basolateral arsenic transport, efflux was measured at 37 C and compared with efflux at 4 C for 5 different SCHH preparations in the presence of þ Ca 2þ HBSS (Fig.   4A ). Efflux was decreased by 87 6 6% (mean 6 SD, n ¼ 5, P < 0.001, Student's t-test) at 4 C compared with 37 C controls (Fig. 4A ).
Similar results were obtained for the biliary efflux of arsenic for SCHH preparation 19 (data not shown). These data suggest a transport process is responsible for basolateral and canalicular membrane translocation of arsenic rather than simple diffusion.
Arsenic Transport Is GSH-Dependent Previous studies have shown that As III and/or MMA III transport by MRP1, MRP2, and MRP4 is GSH-dependent due to the formation of As-GSH conjugates (Banerjee et al., 2014; Leslie, 2012) . To determine if arsenic basolateral efflux is dependent on GSH, SCHH were treated with BSO (500 mM) for 48 h. GSH depletion of SCHH resulted in a 48 6 5% (mean 6 SD n ¼ 5, P < 0.001, Student's t-test) reduction in arsenic efflux compared with 'GSH-normal' controls (10-min time point, 1 mM arsenic treatment) (Fig. 4B, left  panel) . GSH depletion in a single SCHH preparation treated with 0.5 mM arsenic resulted in a 70% reduction in arsenic efflux at 10 min (Fig. 4B, right panel) . These data show that a major portion of arsenic basolateral efflux from SCHH is dependent on the presence of GSH. These data are consistent with MRPdependent basolateral transport of arsenic. SCHH preparations 19, 22, and 23 showed GSH-dependent arsenic transport across both the basolateral and canalicular surfaces of the hepatocyte (Figs. 4B-E) . The BEIs for 19, 22, and 23 at 10 min were decreased to 0% in the presence of BSO indicating that all canalicular arsenic transport is dependent on the presence of GSH (Figs. 4C-E) . These data are consistent with rat in vivo data that Mrp2 is solely responsible for the biliary excretion of arsenic as As(GS) 3 and MMA(GS) 2 (Kala et al., 2000) . MRP2 is the only known GSH-dependent transport pathway at the canalicular surface of human hepatocytes and these results strongly suggest MRP2 is the human arsenic biliary excretion pathway. Na þ /K þ -ATPase band was used to normalize the loading for both samples. To determine if MRP2 levels were increased in a dose-dependent manner, SCHH preparation 23 was treated with 3 different concentrations of As III for 24 h. Relative to its untreated control MRP2 was increased by 1-, 1.9-, and 2.2-fold at 0.1, 0.5, and 1 mM As III , respectively (Fig. 5C ). These results are consistent with previous reports of inorganic arsenic inducing MRP2 mRNA and protein levels in human hepatocytes (Vernhet et al., 2001) .
MRP4 Levels Are Increased by Arsenic in SCHH
To determine if MRP4 was increased by As III treatment 3 different SCHH were treated with a single concentration of As III (1 mM)
for 24 h and MRP4 levels were compared with untreated controls by immunoblot analysis. MRP4 was detected in each of these preparations in the absence of arsenic treatment (Fig. 5D ) although at a relatively low level in SCHH 19. MRP4 levels were modulated by 3.3-, 0.7-, and 1-fold for SCHH preparations 19, 21, and 22, respectively (Figs. 5D and E). To determine if MRP4 levels were increased in a dose-dependent manner, SCHH preparation 23 was treated with 3 different concentrations of As III for 24 h.
Relative to its untreated control MRP4 was increased by 1-, 1.2-, and 1.6-fold at 0.1, 0. D). Relative to its untreated control MRP6 was reduced by 0.9-, 0.6-, and 0.7-fold at 0.1, 0.5, and 1 mM As III , respectively, in SCHH preparation 23 (Fig. 5C ). Relative to its untreated control AQP9 was modulated by 1.7-, 1.2-, and 1-fold at 0.1, 0.5, and 1 mM As III , respectively in SCHH preparation 23 (Fig. 5C ).
Pharmacological Inhibition of Arsenic Transport in SCHH
MK-571 is an LTD 4 receptor antagonist that is commonly used as an MRP inhibitor. To determine if MK-571 inhibited the basolateral efflux of arsenic, SCHH preparation 13 was treated with 100 mM MK-571. This resulted in a 25-50% reduction in arsenic efflux over a 15-min time course (Fig. 6A) .
Phloretin is a commonly used AQP9 inhibitor, reducing permeation of glycerol, MMA time course (Fig. 6B) . Although phloretin is used as an AQP9 inhibitor it is also known to inhibit numerous other unrelated transport proteins (Krupka, 1985; Kwon et al., 2007; Shirasaka et al., 2013; Wang and Morris, 2007) . Phloretin is a bioflavonoid and compounds from this class can be potent inhibitors of MRPs (Wu et al., 2005) . The influence of phloretin on MRP4 activity was unknown, thus the effect of increasing concentrations of phloretin on E 2 17bG transport by membrane vesicles prepared from HEK293 cells over-expressing MRP4 was evaluated. MRP4-dependent transport of E 2 17bG decreased with increasing concentrations of phloretin with an IC 50 value of 53 mM (Fig. 6C) . Therefore, the inhibition of arsenic efflux from SCHH by phloretin could have been mediated by inhibition of MRP4, AQP9, or any other arsenic efflux transporter inhibited by phloretin.
Basolateral and Biliary Arsenic Efflux Is Increased After SCHH Pretreatment With the Nrf2 Activator Oltipraz
Oltipraz is an Nrf2 activator and has been shown to upregulate the expression of several MRPs in human hepatocytes including MRP2, MRP3, and MRP4 (but not MRP6) (Jigorel et al., 2006; Xu et al., 2010) . To determine if SCHH treated with oltipraz (50 lM for 48 h) had altered arsenic efflux, SCHH preparations 19, 22, and 23 were treated with oltipraz and arsenic efflux across the basolateral and canalicular membranes was measured at 10 min (19 and 22) or 15 min (23). SCHH preparations 19, 22, and 23 treated with oltipraz showed a 21 6 4% (mean 6 SD, n ¼ 3, P < 0.0002, Student's t-test) increase in arsenic efflux across the basolateral membrane compared with the untreated control (compare black and gray bars in Fig. 7A ). In contrast, the BEI was either unchanged or reduced for SCHH treated with oltipraz compared with untreated controls (Fig. 7A) . Analysis of MRP4 and MRP2 levels in SCHH preparations 22 and 23 by immunoblot revealed a 1.2-to 3.3-fold increase in expression for both of these MRPs after oltipraz þ As III treatment compared with As III alone (Fig. 7B) . These data are consistent with an important role for MRP4 in the basolateral efflux of arsenic and might suggest that if both MRP2 and MRP4 levels are increased the basolateral efflux of arsenic prevails.
Inorganic and Methylated Arsenic Species Are Effluxed Across the Basolateral Surface of SCHH
To determine the chemical species of arsenic effluxed across the hepatocyte basolateral surface, culture media from 4 different day 6 SCHH preparations treated with 0.5 mM and/or 1 mM As III for 24 h were analyzed by HPLC-ICP-MS (Fig. 8A) . The HPLC-ICP-MS method used can differentiate between trivalent and pentavalent species of arsenic; however, the trivalent forms are easily oxidized in culture media and during sample storage/ preparation. Thus, pentavalent forms identified in culture media are referred to as inorganic arsenic, MMA, and DMA without valency designation. DMA was the major metabolite detected in culture media accounting for 18, 11, 22, and 14% of total arsenic for SCHH preparations 21, 22, 23, and 26, respectively, treated with 0.5 mM As III (Fig. 8A , left panel) and 5 and 9%
for SCHH preparations 22 and 23, respectively, treated with 1 mM As III (Fig. 8A, right panel) . MMA was detected at 4 and 3% of total arsenic for SCHH preparations respectively, treated with 0.5 mM As III (Fig. 8A , left panel) and 2% for SCHH preparation 23, treated with 1 mM As III (Fig. 8A, right panel) .
Experiments were then done to determine the species of arsenic effluxed across the basolateral surface of the hepatocyte under conditions more closely resembling the efflux assay. After treatment with 0.5 mM and/or 1 mM of As III for 24 h SCHH preparations 21, 22, 24, and 26 were washed then incubated with arsenic-free media for 1 h at 37 C. Culture media were then collected and analyzed by HPLC-ICP-MS. DMA was again the major metabolite detected accounting for 14, 7, 26, and 9% of total arsenic for SCHH preparations 21, 22, 24, and 26, respectively, treated with 0.5 mM As III (Fig. 8B , left panel) and 0% for SCHH preparation 22 treated with 1 mM As III (Fig. 8B, right panel) .
Under these conditions only MMA III (and no MMA V ) was detected at 0, 6, 9, and 8% of total arsenic for SCHH preparations 21, 22, 24, and 26, respectively, treated with 0.5 mM As III (Fig. 8B, left panel) and 6.8% for SCHH preparation 22 treated with 1 mM of As III (Fig. 8B right panel) .
These results are consistent with previous reports of arsenic methylation by primary human hepatocytes (Drobna et al., 2004 (Drobna et al., , 2010 Styblo et al., 1999) , variability was seen in the methylation pattern between donors and methylation was reduced with increasing concentrations of arsenic [see Fig. 8A and B, left panels (0.5 mM) compared with right panels (1 mM)]. Overall these results show that SCHH methylate arsenic and that inorganic and methylated forms are being transported across the basolateral membrane of hepatocytes.
DISCUSSION
We present the first characterization of arsenic hepatobiliary transport using primary human hepatocytes cultured in a sandwich configuration. In humans, $80% of ingested arsenic is eliminated in urine, predominantly as methylated metabolites (formed in liver). Consistent with this, 9 out of 14 SCHH preparations had only basolateral hepatic efflux while the remaining 5 had some degree of biliary excretion along with basolateral efflux. Basolateral efflux of arsenic was temperature sensitive, partially GSH-dependent and inhibited by phloretin and MK-571. These characteristics of transport suggest a significant portion of total arsenic basolateral efflux is likely mediated by an MRP. Based on our previous studies one likely basolateral candidate is MRP4 (Banerjee et al., 2014) . Consistent with this, low concentrations of arsenic induced the level of MRP4 in SCHH in a dose-dependent manner. In addition, the Nrf2 activator oltipraz increased the basolateral efflux of arsenic and the levels of MRP4.
Glutathione depletion reduced the basolateral efflux of arsenic by $50%. This partial GSH-dependence is consistent were incubated for 3 min at 37 C in transport buffer with E 2 17bG (1 mM; 80 nCi/pt) in the presence and absence of phloretin (50-500 mM). Points represent means 6 SD for triplicate determinations in a single experiment.
with the ability of MRP4 to transport MMA III as a GSH conjugate and DMA V in a GSH-independent manner (Banerjee et al., 2014) .
Speciation analysis of culture media from cells treated under conditions most closely resembling the 73 As efflux assays (Fig. 8B) revealed that DMA and MMA III were effluxed across the basolateral surface of multiple SCHH preparations, consistent with the substrate specificity of MRP4. Arsenic-GSH conjugates were not detected likely due to their chemical instability in culture media and during sample handling/storage (reviewed in Leslie 2012); however, some of the MMA III in the media could be derived from MMA(GS) 2 . Presumably other transport proteins and channels also contribute to the basolateral efflux of arsenic. This is especially true for inorganic forms, which composed the majority of arsenic species in SCHH culture media (Fig. 8 ), but are not substrates for MRP4. Basolateral efflux of As(GS) 3 by another MRP would fit with the GSH-dependence (Fig. 4B ) and MK-571 inhibition (Fig. 6A ) of total arsenic transport. We have recently shown that the basolateral MRP3 and MRP5 do not confer cellular resistance to inorganic or methylated arsenic species (Banerjee et al., 2014) . MRP6 is also located at the appropriate surface of the hepatocyte for basolateral efflux of arsenic. However, its role in arsenic transport is unknown. MRP6 protein levels were not increased by arsenic treatment suggesting it might not be important, but cytotoxicity and direct transport studies are needed to confirm this. In addition to MRPs, human AQP9 is an efficient pathway for As III and MMA III uptake expressed at the basolateral membrane of human hepatocytes (Lebeck, 2014) . AQPs are bidirectional channels. Thus, if the free concentration of certain arsenic species inside the cell is higher than blood levels, arsenic can potentially pass through AQP9 down its concentration gradient out of the hepatocyte into the blood. AQP9 is capable of transporting only neutral species of arsenic which include As III and MMA III , but not GSH conjugates and the predominant forms of MMA V and DMA V at physiological pH (McDermott et al., 2010) .
GLUTs might also contribute to the GSH-independent transport of inorganic and methylated arsenic species across the basolateral surface of the hepatocyte (Mukhopadhyay et al., 2014) . In contrast with the basolateral efflux of arsenic, biliary efflux was completely lost after depleting hepatocytes of GSH. This observation was consistent with in vivo rat studies that show arsenic biliary excretion results from Mrp2-dependent transport of As(GS) 3 and MMA(GS) 2 (Kala et al., 2000) . The complete lack of biliary excretion in certain SCHH preparations was surprising given the extensive biliary excretion of arsenic which occurs in rats prior to enterohepatic cycling (Cui et al., 2004; Dietrich et al., 2001; Kala, et al., 2000; Suzuki et al., 2001) . Arsenic has been detected in bile from patients with T-tubule drainage post-gallstone removal, suggesting arsenic can undergo biliary excretion in humans (Ishihara and Matsushiro, 1986) . This study was somewhat limited by the small patient number (n ¼ 3) and the pathological state. A second study of healthy humans dosed orally with 74 As showed that 6% of the arsenic dose was recovered in feces; however, it is not known if this was unabsorbed or from intestinal/biliary excretion (Pomroy et al., 1980) . Thus, very little information exists regarding the hepatobiliary handling of arsenic in humans.
The increased efflux of arsenic under Ca 2þ -free compared with Ca 2þ -containing conditions in 5 SCHH preparations showed that this model is suitable for the detection of both basolateral and biliary excretion of arsenic. Experimental conditions should have promoted biliary excretion of arsenic because SCHH were allowed to metabolize and accumulate arsenic in canalicular networks for 24 h prior to measuring efflux. Despite this, basolateral efflux was the only efflux detected in the majority of the preparations. The reasons for variations in the extent of biliary excretion of arsenic between the human hepatocyte preparations used in this study are not clear. One obvious possibility would be a lack of functional MRP2 in preparations lacking biliary excretion. However, accumulation of the MRP2 substrate CDF in the canalicular networks of SCHH preparations that did not transport arsenic into bile argues against this possibility. Another possible explanation for a lack of biliary efflux could be that arsenic reduces the integrity of the canalicular networks preventing its accumulation. However, CDF was still accumulated in canalicular networks of SCHH preparation pretreated with As III , suggesting that networks were intact. Based on the GSH-dependent nature of arsenic biliary excretion observed with SCHH and previous studies with rats (Kala et al., 2000) , human MRP2 is predicted to play a major role in the biliary excretion of arsenic in humans. However, we found that MRP2 protein levels did not dictate the extent of biliary excretion when MRP2 levels were evaluated using whole cell lysates. However, this does not preclude the possibility that the levels of functional MRP2 residing in the plasma membrane accounts for the extent to which arsenic undergoes biliary excretion. MRP2 (gene symbol ABCC2) is known to be highly polymorphic and there could be genetic variation in ABCC2 expressed in these SCHH preparations that influences arsenic transport activity. Factors other than MRP2 (e.g., basolateral efflux pathways and methylation), could also influence the extent of arsenic biliary excretion. Although it is known that As(GS) 3 is transported by human MRP2 little is known about its ability to transport methylated arsenic metabolites. (Csanaky and Gregus, 2002; Kala et al., 2000) . Therefore, it is possible that MMA(GS) 2 is a major metabolite formed in the hepatocyte but in humans it does not undergo biliary excretion. The extent and pattern of arsenic methylation is known to vary greatly between primary human hepatocyte preparations (Drobna et al., 2004 (Drobna et al., , 2010 Styblo et al., 1999) and similar variability was observed with the SCHH model (Fig. 8) . It is almost certain that the arsenic species formed in the hepatocyte will influence the extent of biliary versus basolateral excretion, depending on the substrate specificity and affinity of the canalicular and sinusoidal transport pathways for different species of arsenic. In addition to methylation and efflux pathways it is important to consider the extent of arsenic cellular accumulation and how this might influence the degree of biliary and basolateral efflux. Accumulation of arsenic in the 4 SCHH preparations varied $ 2-fold ( Supplementary Fig. S1B ) and a previous study using primary human hepatocytes cultured on a single layer of collagen reported a variation of 3-to 4-fold (Drobna et al., 2004) . Although this difference in accumulation could have a direct effect on the extent of basolateral and biliary efflux, several data in the current manuscript suggest this is not the case. To begin with, it is known that there is a linear relationship between the concentration of As III in cell culture media and accumulation by primary human hepatocytes up until at least 10 mM As III (Drobna et al., 2004) . Despite this, the initial concentration of As III did not influence the polarized transport of total arsenic (Fig. 3) . Furthermore, while SCHH preparations 2 and 5 had very similar accumulation levels (Supplementary Fig. 1B , respectively) SCHH 2 had $8-fold lower efflux activity at 10 min than SCHH 5 ( Fig. 1C compared with 1E) . SCHH 2 also exhibited moderate biliary excretion while SCHH 5 did not (Figs. 1C and E) . Accumulation of arsenic was also similar for SCHH 4 and 26, but unrelated to efflux activity (Fig. 1D., Fig. 1O , and Supplementary Fig. 1B ). These data suggest accumulation does not dictate the extent or direction of efflux.
MRP4 is a high-affinity transporter of MMA(GS) 2 and DMA can transport MMA(GS) 2 or DMA V it is a well-characterized transporter of As(GS) 3 with a lower affinity (K m of 4.2 lM) (Carew and Leslie, 2010) compared with MRP4 transport of MMA(GS) 2 and DMA V . Thus at low concentrations of arsenic, it would be expected that MRP4 would transport the majority of DMA V and MMA(GS) 2 out of the hepatocyte, thus shunting arsenic into blood rather than bile. This is consistent with the oltipraz induction of MRP2 and MRP4 that resulted in increased basolateral efflux of arsenic with no change in the BEI. Thus, polymorphic variants of MRP4 or other basolateral arsenic transporters might have more influence on the polarity of arsenic transport than polymorphic variants of MRP2. In summary, the physiologically relevant SCHH model has been used to characterize human hepatobiliary excretion of arsenic. Consistent with the predominant urinary excretion of arsenic in humans, basolateral transport was the prevailing pathway. Characteristics of the basolateral transport of arsenic suggest it is mediated at least in part by an MRP. This study in combination with previous work (Banerjee et al., 2014) , suggest that MRP4 is a likely candidate. GSH-dependent hepatic basolateral transport pathways for inorganic arsenic are yet to be identified. Previous studies have shown a strong correlation between xenobiotic in vivo bilary excretion and the BEI determined using human and rat SCH (Ghibellini et al., 2007; Liu et al., 1999a) . This study strongly suggests that inter-individual differences exist in the extent of biliary excretion of arsenic in humans. The possibility that genetic differences among human hepatocyte donors (in both efflux and methylation pathways) contribute to altered canalicular and basolateral transport pathways is worthy of further investigation.
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